1,614 reports of this reaction
2.0% of all OFATUMUMAB reports
#8 most reported adverse reaction
MULTIPLE SCLEROSIS RELAPSE is the #8 most commonly reported adverse reaction for OFATUMUMAB, manufactured by Novartis Pharmaceuticals Corporation. There are 1,614 FDA adverse event reports linking OFATUMUMAB to MULTIPLE SCLEROSIS RELAPSE. This represents approximately 2.0% of all 82,579 adverse event reports for this drug.
OFATUMUMAB has an overall safety score of 78 out of 100. Patients taking OFATUMUMAB who experience multiple sclerosis relapse should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
MULTIPLE SCLEROSIS RELAPSE is a less commonly reported adverse event for OFATUMUMAB, but still significant enough to appear in the safety profile.
In addition to multiple sclerosis relapse, the following adverse reactions have been reported for OFATUMUMAB:
The following drugs have also been linked to multiple sclerosis relapse in FDA adverse event reports:
MULTIPLE SCLEROSIS RELAPSE has been reported as an adverse event in 1,614 FDA reports for OFATUMUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
MULTIPLE SCLEROSIS RELAPSE accounts for approximately 2.0% of all adverse event reports for OFATUMUMAB, making it a notable side effect.
If you experience multiple sclerosis relapse while taking OFATUMUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.